Astellas Pips Janssen To Post With English Funding For New Prostate Cancer Indication
Executive Summary
NICE’s decision today affirming the cost effectiveness of Astellas Pharma’s Xtandi for hormone-sensitive metastatic prostate cancer contrasts with the health technology assessment body’s guidance last month for Janssen’s Erleada.
You may also be interested in...
NICE Reverses English Funding Rejection For Erleada After Janssen Drops Price
The androgen receptor inhibitor Erleada is now considered to be a cost-effective use of National Health Service resources.
Frustration Over English Funding Rejection For Zytiga And A Win For Ledaga
Janssen and UK health technology assessment body NICE are being urged to sit down together and agree a suitable price for using Zytiga as a first-line treatment for advanced prostate cancer.
Alexion’s Ultomiris Wins English Funding, Janssen’s Erleada Rejected
Recommendations this week from health technology assessment body NICE relate to the treatment of two rare blood disorders with Ultomiris, and treating prostate cancer with Erleada.